High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Patients must have FDG-avid and histologically or cytologically proven non-small cell lung cancer. * Age 1 8-75. * Eastern Cooperative Oncology Group （ECOG） performance status 0 to 2. * Stage III ( American Joint Committee on Cancer AJCC, 7th ed.). * No prior radiation to the thorax that would overlap with the current treatment field. * Adequate bone marrow, renal and hepatic functions as assessed by the following: Hemoglobin \>/= 10.0 g/dl, Platelet count \>/= 1 00,000/ mm\^3,absolute granulocyte count (AGC) ≥2 × 10\^9 cells/L,bilirubin and Aspartate transaminase ≤1.5 ×upper limit of normal (ULN), Creatinine \</ =1 .5 times ULN. * A signed informed consent must be obtained prior to therapy. * Induction chemotherapy is allowed. * Life expectancy more than 3 months Exclusion Criteria: * Patients with any component of small cell lung carcinoma are excluded from this study. * Patients with evidence of a malignant pleural or pericardial effusion are excluded. * Prior radiotherapy that would overlap the radiation fields. * Uncontrolled concurrent illness including, but not limited to: Chronic Obstructive Pulmonary Disease(COPD) exacerbation or other respiratory illness, serious uncontrolled infection, symptomatic congestive heart failure (CHF),unstable angina pectoris, uncontrolled hypertension,or psychiatric illness/social situations that would limit compliance with the study requirements. * Known hypersensitivity to paclitaxel. * Any other condition or circumstance that would, in the opinion of the Investigator, make the patient unsuitable for participation in the study. * Conditions precluding medical follow-up and protocol compliance